Nobles Medical Technologies II Receives Significant Japanese Patent
For “SUTURING DEVICES AND METHODS FOR CLOSING A PATENT FORAMEN OVALE” Using It’s NobleStitch™ Technology
Fountain Valley, California—Wednesday, March 16, 2016— Nobles Medical Technologies II (NMT2) today announced that it has received another Patent for the NobleStitch™ Technology which provides coverage for its PFO device in Japan. The patent is for “Suturing Devices and Methods for Closing Patent Foramen Ovale (PFO)”. This patent provides NMT2 broad coverage of its method and apparatus claims for closing PFO in Japan; PFO closure is the core business of the NMT2 portfolio.
Prof. Anthony Nobles, CEO of NMT2 and co-inventor on the issued patent commented, “Intellectual Property is one of the most valuable assets we have. Particularly on our primary revenue driver the NobleStitch™ EL. In the medical device industry patents represent one of the greatest measurements of the value of a Company. This patent carries broad coverage for specific indication of PFO closure in Japan, which is one of our next target markets.”
Ben Brosch, President of NMT2 and co-inventor on the issued patent commented, “We strive to protect our inventions with strong patents that help us maintain a technological advantage. Our shareholders often ask me about our patents - where are they issued, how long will they be enforceable? This is why we are proud to expand the coverage of our intellectual property around the world and continue to protect our technology for the future. We actively file new patents and continue to grow an extensive portfolio of patents and trademarks adding value to our company and its shareholders.”
Rich Babcock, a Director of NMT2, stated, “Patents are a difficult and expensive processes to take from conception through issuance. There is extensive legal and technical expertise required, particularly when filing in foreign countries. Prof. Nobles has successfully authored more than 75 patents in the US and throughout the world. His continued innovation is one of our greatest assets as a technology company and his knowledge of intellectual property is exceptional. NMT2 is committed to continuing to increase its worldwide patent portfolio, and this new issuance is another example of the successful commitment of our team”.
About PFO Closure
A PFO is a relatively common heart defect characterized by an unsealed tunnel between the right and left atria of the heart. This defect has been known to be present in anywhere between 27%-38% of people. However, in a number of cases, it is benign.
The PFO is formed as a trace of the fetal circulation. When the chambers of a human heart begin to develop, a tunnel is made between the right and left atria, allowing blood to flow directly from the venous circulation to the arterial circulation, circumventing the non-functioning fetal lungs. Following birth, the pressure differential between the right and left atria changes with newly operational blood flow to the fully functioning lungs. Because of this, the tunnel eventually closes completely within the first few months.
However, in some patients, the foramen ovale fails to seal and stays "patent". In patients with a Patent Foramen Ovale (PFO), the tunnel can reopen under elevated atrial pressure, such as coughing, or straining.
A key issue with PFO is that it gives a pathway for blood clots to pass directly to the arterial circulation without being filtered out by the capillary bed of the lungs. A PFO can also let deoxygenated blood and certain chemicals to cross over to the arterial side. The presence of a PFO has been linked to a number of clinical issues, mainly strokes, migraines and chronic fatigue. Developments are being made to solidify the link between PFO and strokes or migraines, and to identify patients that would benefit from PFO closure.
For more information, please contact shareholder representatives:
Dru Dobbs
P. +1 714 427 6348
F. +1 714 427 6343
About Nobles Medical Technologies II
Nobles Medical Technologies II, Inc. was founded by Prof. Anthony Nobles to leverage its technologies in the PFO and ASD closure marketplace. The company does business under the name of Nobles Medical II (NMT II). Initial efforts of the company are focused on the innovative suture-based PFO closure system for closing the Patent Foramen Ovale (PFO), a tunnel between the right and left atria of the heart and suturing vascular structures.
The NobleStitch™ is approved for PFO Closure and Cardiovascular suturing in the European Union. The NobleStitch™ EL is FDA cleared for vascular suturing in the United States.
NobleStitch™ EL is distributed worldwide by HeartStitch®, Inc. (HeartStitch® is a registered trademark of HeartStitch®, Inc.)
For more on Nobles Medical Technologies II visit www.NoblesMedicalTechnology.com
Tags:
